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A type of hair loss closely resembling human alopecia
areata has been described in C3H/HeJ mice. In
order to test the assumed analogy with human
alopecia areata, we investigated the efficacy of
treatment with the contact allergen squaric acid
dibutylester. In 12 C3H/HeJ mice with alopecia
areata an allergic contact dermatitis was induced
and elicited weekly on one side of the back by
topical applications of squaric acid dibutylester.
Overt hair regrowth was observed only on the
treated side of the back in nine of 12 mice.
Histopathologic examination revealed a change in
the distribution of the inflammatory infiltrate from
a dense perifollicular lymphocytic infiltrate around
the mid and lower regions of hair follicles in
untreated skin to a uniform presence in the upper
dermis in treated skin. Immunohistomorphometric
studies revealed that treatment with squaric acid
dibutylester increased the CD4F/CD8F ratio from
approximately 1:2 in untreated alopecia areata to 1:1
in treated alopecia areata. Additional immunohisto-
Alopecia areata (AA) is a common human diseasewith a lifetime risk of 1.7% in the general population(Safavi et al, 1995). It is characterized by a reversiblepatchy hair loss that may sometimes lead tocomplete baldness. Histopathologic features of AA
include perifollicular lymphocytic infiltrates involving the anagen
hair follicles with subsequent miniaturization of these follicles
(Gollnick and Orfanos, 1990). The pathogenesis of AA is poorly
understood, but a peribulbar and intrabulbar accumulation of T
lymphocytes (Perret et al, 1984) and an aberrant expression of
intercellular adhesion molecule 1 (ICAM-1) and HLA-DR
molecules on follicular keratinocytes and dermal papillae (Hamm
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chemical investigations showed an aberrant expres-
sion of major histocompatibility complex class I,
major histocompatibility complex class II and inter-
cellular adhesion molecule 1 on keratinocytes of the
mid and lower parts of hair follicles in untreated
alopecia areata. In successfully treated skin ectopic
major histocompatibility complex class I and II
expression was clearly reduced, whereas intercellular
adhesion molecule 1 expression showed only minor
changes. In conclusion, alopecia areata-like hair loss
in C3H/HeJ mice responded to treatment with the
contact sensitizer squaric acid dibutylester analogous
to human alopecia areata. Moreover, successful
treatment changes the aberrant expression of major
histocompatibility complex class I and II in a way
similar to that observed in human alopecia areata.
These observations support the concept that alopecia
areata-like hair loss in C3H/HeJ mice can be utilized
as an appropriate model for the study of human
alopecia areata. Key words: CD4/CD8/major histo-
compatibility complex class I/major histocompatibility
complex class II. J Invest Dermatol 113:61–68, 1999
et al, 1988; Nickoloff and Griffiths, 1991) provide evidence that
an immune process is involved (Baadsgaard, 1991).
Induction and periodic elicitation of an allergic contact
dermatitis is currently the most effective mode of treatment
(Hoffmann and Happle, 1996). The mode of action, however,
by which topical immunotherapy induces hair regrowth in AA
remains to be elucidated. For obvious reasons, many therapeutic
strategies cannot be tested in human patients with AA. Hence,
a suitable animal model would be helpful to investigate the
mechanism of the effect of topical immunotherapy and to
develop new therapeutic approaches that should be more specific
than the induction of an allergic contact dermatitis.
Several animal species have been reported to develop hair
loss resembling human AA, including dogs, cats, horses, rodents,
and nonhuman primates (Conroy, 1979; Michie et al, 1991;
Sundberg et al, 1995; McElwee et al, 1998). In the larger species,
AA is poorly characterized, the animals are outbred, and they
are not readily available for study which makes them of little
practical use as research models. A type of reversible hair
loss, that closely resembles human AA both clinically and
histopathologically, has been described in aging C3H/HeJ mice
(Sundberg et al, 1994). This disease arises spontaneously with a
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Table I. Primary antibodies, sources, host species, and dilutions
Antigen Clone Source Species Dilution
CD4 (L3T4) RM4–5 Pharmingen Rat 1:500
CD8 (Lyt-2) 53–6.7 Southern Biotechnology Rat 1:500
MHC Class I ER MP 42 BMA Rat 1:200
MHC Class II ER-TR 3 BMA Rat 1:500
ICAM-1 KAT-1 ATCC Rat 1:50
low frequency in mice beginning at about 6 mo of age, and
in some colonies the expression frequency can approach 20%
by 18 mo of age. Affected animals first develop patchy hair loss
on both ventral and dorsal surfaces. Spontaneous hair regrowth
occurs in 2%–3% of affected mice whereas 10% of affected mice
develop subtotal or total hair loss. Histopathologic examination
shows that these mice develop nonscarring alopecia with
dystrophic anagen hair follicles surrounded by mononuclear cell
infiltrates with a predominance of CD81 lymphocytes and small
numbers of CD41 cells. Telogen hair follicles are not affected.
Recently, circulating autoantibodies to hair follicle antigens,
similar to those present in human patients with AA, have been
found in C3H/HeJ mice with AA (Tobin et al, 1997).
In order to determine whether this mouse disorder can be
treated in the same way as human AA we treated AA affected
C3H/HeJ mice with the contact allergen squaric acid dibutylester
(SADBE). Successfully treated skin was examined for histopathol-
ogic and immunologic changes comparable with those observed
in humans.
MATERIALS AND METHODS
Animals Studies were conducted on 16 C3H/HeJ mice (15 females,
one male) with AA-like hair loss (Sundberg et al, 1994). Twelve mice
were treated by topical immunotherapy, and four mice received the
vehicle alone. The group that received topical immunotherapy consisted
of five mice with large bald patches and seven with total hair loss on
their dorsal skin. In the control group, three mice had patchy and one
had subtotal hair loss. Mice were provided by the Jackson Laboratory
(Bar Harbor, ME). Animals were housed, one per cage, with controlled
light cycles of 12–12 h light/dark and fed with acidified water (pH 2.8–
3.2) and conventional diet (altromin 1324, Altromin GmbH, Lage,
Germany) ad libitum.
Treatment Twelve mice were sensitized on a 1.0 3 1.0 cm area of
the left side of the back with 2% SADBE in acetone. Starting 1 wk
later, we treated the left half of the dorsal skin by weekly topical
applications of 0.1%, 0.5%, or 1% SADBE in acetone. The right side
of the back remained untreated. The concentration and total volume
of the contact allergen was chosen individually until a moderately severe
contact dermatitis, lasting for 2–3 d, was induced. Treatment was started
with the lowest concentration (0.1% SADBE) and thereafter escalated
individually until a moderately severe dermatitis occurred. The appropriate
concentration of SADBE was maintained until the end of treatment.
In this way one mouse was treated with 0.1% SADBE, six mice with
0.5% SADBE and five mice with 1% SADBE. Treatment was continued
until complete regrowth on the treated side was achieved, but no
longer than 5 mo (two mice were treated for 7 wk, three mice for
11 wk, two mice for 13 wk, two mice for 14 wk, two mice for
19 wk, one mouse for 21 wk). Four control mice were treated by
weekly topical applications of acetone on the left side of the back for
10 wk. Morphologic changes were examined and documented daily.
Photographs were taken before, during, and after treatment. At the end
of treatment two investigators who were not involved in the treatment
of mice categorized the animals as responders or nonresponders according
to macroscopic examination. Only those mice showing hair regrowth
limited to the treated side were regarded as successfully treated.
Histopathologic examination At the end of treatment mice were
anesthesized and their dorsal skin was shaved. Afterwards the animals
were killed by cervical dislocation. Representative portions of both
treated and untreated skin were removed and snap-frozen in liquid
nitrogen. Eight to 10 µm vertical sections were stained with hematoxylin–
eosin and examined by light microscopy. In order to determine the
localization of perifollicular and intrafollicular infiltrates their presence
in the following four compartments was analyzed and compared in
treated and untreated skin of every mouse: B, in and around the bulbar
and suprabulbar region of the hair follicle; M, along the mid part of
the hair follicle between bulb and sebaceous gland; U, along the upper
part of the hair follicle above the sebaceous gland; D, in the interfollicular
space of the dermis (Fig 5).
Immunohistochemistry Untreated and treated skin was snap-frozen
in liquid nitrogen for immunohistochemistry immediately after the
animals were killed. Frozen vertical sections, 8–10 µm thick, were fixed
in acetone for 10 min at –20°C and air dried. Between all incubation
steps sections were washed three times for 5 min with Tris-buffered
saline (0.05 M, pH 7.6). Non-specific binding was blocked by application
of an avidin–biotin blocking kit solution (Vector Laboratories, Burlingame,
CA) as well as by 2% bovine normal serum and 2% goat normal serum
in Tris-buffered saline. Thereafter, the slides were incubated with the
primary antibody, diluted in Tris-buffered saline containing 2% normal
bovine serum at room temperature for 1 h. Sources, host species, and
concentrations of primary antibodies used are listed in Table I. After
washing, sections were incubated with the secondary, biotinylated goat
anti-rat antibody (Dianova, Hamburg, Germany), diluted 1:150 in Tris-
buffered saline containing 4% mouse normal serum and 2% goat normal
serum for 30 min at room temperature. After washing a routine staining
method for avidin–biotin complex labeled with alkaline phosphatase was
used (Vector Laboratories, Burlingame, CA) and counterstained with
Mayer’s hematoxylin. Negative controls included replacement of primary
antibody by normal rat IgG.
For major histocompatibility complex (MHC) class I and II, and
ICAM-1 the intensity and distribution of staining was assessed by use
of the following scoring system: no expression; mild expression, weak or
intermediate intensity of staining of the minority (,50%) of hair
follicles; moderate expression, weak staining of the majority (.50%), or
intense staining of the minority of hair follicles; severe expression,
intermediate or intense staining of the majority of hair follicles. To
analyze anatomic and functional different regions of the hair follicle,
four parts of it were assessed separately: P, dermal papilla; B, bulbar
and suprabulbar region; M, mid part of hair follicle between the bulb
and sebaceous gland; U, upper part of hair follicle above the sebaceous
gland. In the epithelial compartments, staining patterns of inner (IRS)
and outer (ORS) root sheath were examined separately. Immunoreactivity
of the dermis was assessed qualitatively. In this way, MHC class I and
II and ICAM-1 expression was compared in skin of untreated and
treated AA as well as in normal anagen skin obtained from three
unaffected C3H/HeJ mice. Because of the heterogeneous expression of
the assessed surface molecules, a comparison was made in each individual
mouse before and after therapy.
Histomorphometry This technique was performed to determine the
number of perifollicular and intrafollicular CD41 and CD81 lymphocytes.
Video images of the entire length of longitudinally cut hair follicles were
stored by means of a Lucia M image analysis system (Nikon, Du¨sseldorf,
Germany). Perifollicular and intrafollicular immunoreactive cells were
counted on digital images at 10-fold magnification using LUCIA M
software version 2.995β (Nikon). At least five intact longitudinal hair
follicles were analyzed in serial sections for CD41 and CD81 lymphocytes
on their entire length below the sebaceous gland. The mean cell numbers
of positive cells per hair follicle served as a basis for calculating the CD41/
CD81 ratio before and after therapy for every mouse.
Statistical analysis Statistical significance of unilateral hair regrowth was
estimated using the Mann–Whitney U test. The changes in the number
of perifollicular CD41 and CD81 cells before and after treatment as
assessed by histomorphometry were analyzed by t test for paired samples.
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Figure 1. AA-like hair loss in C3H/HeJ mouse was successfully
treated unilaterally with SADBE. Distinct hair regrowth on the left
side of the back treated with SADBE for 15 wk. The untreated right side
served as a control and remained bald.
RESULTS
Unilateral hair regrowth occurred after SADBE treat-
ment After elicitation with the individually determined con-
centration of SADBE all mice treated with SADBE developed
a mild to moderately severe contact dermatitis strictly limited
to the treated side of the back. The allergic response was
characterized by erythema 1 d after application of SADBE in
five of 12 mice. After 2 d in all mice increasing scaling and
excoriations lasting for 3 d were noted. Subsequently, the signs
of contact dermatitis decreased until the next treatment.
In nine of 12 mice a dark pigmentation of some areas of the
treated side appeared after 3–12 wk of treatment whereas the
untreated side remained pink or gray. Shortly thereafter definite
hair regrowth was observed initially in the pigmented regions
and subsequently in a normal density. The untreated side did
not show any pigmentation or hair regrowth (Fig 1). Hair
regrowth continued during the following 4 wk of treatment.
These nine of 12 mice were classified as successfully treated
(p ø 0.01).
In two of 12 mice with patchy alopecia, pigmentation and
regrowth occurred on both sides but were more pronounced
on the treated side. One of 12 mice did not show any regrowth
after 5 mo of therapy. In this mouse a severe contact dermatitis
with subsequent scarring had developed after application of 1%
SADBE. Four of four control mice did not show any eczema
or unilateral hair regrowth.
Lymphocytic infiltrates predominate in untreated skin
around the lower parts of hair follicles and in treated skin
in the dermis Histopathologic examination revealed that
untreated skin (Figs 2a and 5b) contained anagen hair follicles
showing a dense perifollicular and sometimes intrafollicular
lymphocytic infiltrate with an admixture of some granulocytes.
Most of the affected hair follicles were reduced in size and
showed hair shaft dystrophy as well as pigmentary incontinence.
In five of nine mice the infiltrate was present in the bulbar
and suprabulbar region and along the hair follicle up to the
sebaceous gland (compartment B and M), in four of nine hair
follicles it was exclusively present along the hair follicle between
bulb and sebaceous gland (compartment M). In successfully
treated skin (Figs 2b and 5c) the inflammatory infiltrate consisting
of lymphocytes and neutrophils showed a rather diffuse distribution
throughout the interfollicular space of the dermis (compartment
D) and a less pronounced presence along the mid and upper
parts of the hair follicles (compartment M and U) in seven of
Figure 2. After treatment the lymphocytic infiltrates no longer
show a predilection for the perifollicular area at the mid region of
hair follicles but are diffusely distributed throughout the dermis.
Staining of cryostat sections with hematoxylin and eosin. (a) Dystrophic
anagen hair follicle with dense perifollicular lymphocytic infiltrate
between the bulb and sebaceous gland (compartment M) in untreated AA.
(b) Widespread lymphocytic infiltrate in perifollicular and interfollicular
dermis in successfully treated skin.
nine mice (Table II). In two of nine successfully treated mice
a diffuse dermal infiltration was similarly present but the
perifollicular infiltrate remained unchanged. Most of the hair
follicles were in anagen and of normal size. The epidermis showed
consistent thickening and orthokeratosis and parahyperkeratosis.
Pigmentation was apparent in the interfollicular epidermis with
no restriction to the hair follicle. Occasional pigmentary
incontinence was noted in the dermis. Skin biopsy of the mouse
that did not show any hair regrowth revealed scarring features
in the upper dermis.
CD4F/CD8F ratio increased after SADBE treatment In
untreated skin CD81 cells predominated over CD41 cells in
the perifollicular lymphocytic infiltrate with a mean CD41/
CD81 ratio of 1:2. Furthermore, CD81 cells were localized
mainly in the center of the infiltrate in close vicinity to, or
within, the hair follicle epithelium (Figs 3b and 5b). CD41
cells were more numerous in the periphery of the infiltrate
(Figs 3a and 5b). After SADBE treatment, the number of
infiltrating CD41 and CD81 cells decreased (Figs 3c, d and
5c), which was due to a reduction of CD81 cells, whereas the
number of CD41 cells had slightly increased (Table III). A
mean CD41/CD81 ratio of 1:1 after SADBE treatment reflects
a substantial change within perifollicular inflammatory infiltrates.
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Hair follicle epithelium in mouse AA showed aberrant
expression of MHC class I (Figs 4a, b and 5a, b) In
unaffected anagen skin of all three healthy control mice a
moderate MHC class I expression was found in the ORS of
the upper part of the hair follicle above the sebaceous gland
(U). The infrasebaceous parts of the hair follicle epithelium (B,
M) were negative for MHC class I. The dermal papilla (P)
showed a mild MHC class I expression. In AA skin the MHC
class I expression of the upper part U was severe in all mice.
Moreover, there was a severe expression of MHC class I on
the ORS of the suprabulbar infrasebacous part (M) of all mice.
In addition, a mild expression on the IRS of part M was seen
in four of nine animals. In the bulbar region (B) a severe
expression on the ORS for MHC class I was found in six of
nine cases, a mild expression in one of nine and no expression
in two of nine. The IRS of part B was negative in all animals.
The dermal papilla showed a moderate or severe expression in
seven of nine cases. The inflammatory infiltrate itself showed
only weak MHC class I positivity in some cells.
Expression of MHC class I on hair follicle epithelium
decreased after SADBE treatment (Figs 4c and 5c) When
the degree of MHC class I expression in the three epithelial
hair follicle compartments B, M, and U in each mouse before
and after therapy was compared, a reduction or total absence
of staining of part B and M, but no difference in the staining
of part U was found in eight of nine mice. In one of nine
mice no difference in MHC class I expression before and after
therapy was noted (Table II). The dermal papilla (P) showed
a reduced or absent staining for MHC class I in five of nine
cases. As before therapy the perifollicular infiltrate showed only
partial and faint expression.
MHC class II was expressed ectopically on hair follicle
epithelium in murine AA (Figs 4d, e and 5a, b) In normal
control mice a moderate or severe expression of MHC class II
was found on the follicular epithelium of the suprasebaceous
part U of the hair follicle. In the lower parts B and M only
Figure 3. CD8F T cells predominate over CD4F T cells in the
lymphocytic infiltrate of untreated mouse AA, and are reduced
after treatment with SADBE. Immunohistochemical staining for
CD4 (a, c) and CD8 (b, d) of untreated (a, b) and treated (c, d) murine
AA. (a) Localization of CD41 cells mainly in the periphery of the infiltrate.
(b) High number of CD81 cells, localized predominantly in the center
of the infiltrate in close vicinity to, or within, the hair follicle epithelium.
(c) Increased number of CD41 cells in the dermis and around upper parts
of hair follicles. (d) Distinct reduction of perifollicular CD81 cells.
single cells situated in the connective tissue sheath showed
expression of MHC class II (Fig 4d). The dermal papilla P was
negative in one of three control mice, and in two of three
MHC class II expression was mild or moderate. In AA mice
the MHC class II expression increased to a severe expression
in the upper part U and the ORS of part M in all animals, a
moderate or severe expression on the IRS of part M in six of
nine mice and a mild to severe expression on the ORS of part
B in eight of nine mice. The dermal papilla showed a mild or
moderate staining for MHC class II in all cases. The infiltrating
cells were stained very strongly for MHC class II.
Figure 4. Aberrant expression of MHC class I and II and ICAM-1
in hair follicle epithelium is present in untreated mouse AA,
whereas MHC class I and II expression is downregulated by SADBE
treatment. Immunohistochemical staining for MHC class I (a–c), MHC
class II (d–f ), and ICAM-1 (g–i ) of skin of healthy control mice (a, d, g),
untreated mouse AA (b, e, h), and successfully treated skin (c, f, i ). (a) No
expression of MHC class I on keratinocytes of bulbar region (B) and weak
expression on dermal papilla in a control mouse (P); (b) positive staining
for MHC class I on keratinocytes of bulb (B) and dermal papilla (P) in
untreated AA; (c) no staining for MHC class I in parts B and P after
treatment; (d) only single MHC class II positive cells in the connective
tissue sheath in a control; (e) positive staining for MHC class II on hair
follicle epithelium of parts B and M in untreated AA; ( f ) negative staining
for MHC class II after treatment; (g) no ICAM-1 expression in hair
follicle bulb of a control; (h) intense staining for ICAM-1 of follicle
epithelium of dystrophic anagen hair follicle, part M, in untreated AA;
(i ) no ICAM-1 expression on keratinocytes of part B in treated skin,
weak staining of dermal papilla. Notice the intense positive staining
for MHC class I and II and ICAM-1 of lymphocytes in untreated AA
(b, e, h).
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Expression of MHC class II on hair follicle epithelium
decreased after treatment (Figs 4f and 5c) A longitudinal
comparison of MHC class II expression on the follicular
epithelium before and after topical immunotherapy in each
mouse revealed a reduced or absent expression in part B and
M after therapy in six of nine cases (Table II), whereas no
difference could be observed in part U. Staining of the dermal
papilla (P) was reduced or absent in only four of nine cases.
The dermis contained a large number of cells that were strongly
positive for MHC class II.
ICAM-1 is expressed on the epithelium of affected hair
follicles (Figs 4g, h and 5a, b) In normal control mice there
was no expression of ICAM-1 on the follicular epithelium, and
the expression on the dermal papilla was only weak. In AA
skin staining for ICAM-1 was mainly found in part M of the
hair follicle in all animals with a mild to severe expression on
the ORS in nine of nine mice and a mild expression on the
IRS in six of nine. By contrast part U showed only a weak
expression in all cases and on the ORS of part B ICAM-1 was
mildly positive in only three of nine cases. The dermal papilla
showed an expression of varying degree in eight of nine cases
and no staining in one of nine mice. Many cells of the
inflammatory infiltrate were positive for ICAM-1.
Table II. Number of mice in whom SADBE treatment induced a change in the distribution of inflammatory infiltrates or
a reduced aberrant expression of MHC class I and II, ICAM-1 in the lower parts B and M of the hair follicle
Inflammatory MHC class I MHC class II ICAM-1
infiltrate
Changed distribution from around lower hair 7/9 Reduced aberrant staining of the 8/9 6/9 4/9
follicle to dermis lower hair follicle
No change in distribution 2/9 No reduction of staining of the lower 1/9 3/9 5/9
hair follicle
Figure 5. The perifollicular infiltrate of CD41 and CD81 T cells shows a shift from around lower hair follicles to dermis after SADBE
treatment and this is accompanied by reduced abnormal expression of MHC class I and MHC class II on the epithelium of lower hair
follicles. (a) Normal control mouse: MHC class I and II are only expressed in part U of the hair follicle epithelium. ICAM-1 is not expressed. (b)
Untreated mouse AA: CD81 T cells predominate and are localized in the center of the perifollicular lymphocytic infiltrate. CD41 T cells in the periphery.
MHC class I and II expression involves part U and M as well as the ORS of part B of hair follicle epithelium. ICAM-1 expression mainly involves part
M and is weak on part U. Note the close spatial relationship between MHC class I and II and ICAM-1 expression and the lymphocytic infiltrate. (c)
Successfully treated AA: CD41 and CD81 T cells in perifollicular and interfollicular dermis. MHC class I and II, and ICAM-1 are present in part U and
M (MHC class I and II only in ORS of M). CTS, connective tissue sheath, SC, sebaceous gland, P, dermal papilla, U, upper, suprasebaceous part of hair
follicle, M, mid part of hair follicle between sebaceous gland and hair bulb, B, bulbar and suprabulbar part of hair follicle.
ICAM-1 expression in the suprasebaceous hair follicle
epithelium increased after treatment (Figs 4i and 5c) An
increased expression of ICAM-1 in the suprasebaceous part U
was observed in five of nine mice after therapy. A reduced or
absent ICAM-1 expression in part B or M could only be found
in four of nine mice, whereas no change could be seen in five
of nine mice (Table II). Staining of the dermal papilla was
reduced or absent in four of nine cases. In the lower part of
the dermis there was a large number of cells that were ICAM-
1 positive.
DISCUSSION
The results of our study show that in C3H/HeJ mice with AA-like
hair loss treatment with the contact sensitizer SADBE dissolved in
acetone induces hair regrowth whereas control animals treated with
the vehicle alone remained bald. Moreover, in order to rule out the
possibility that hair regrowth was due to spontaneous remission,
unilateral treatment was performed as described for topical immuno-
therapy in humans (Happle and Echternacht, 1977; van der Steen
et al, 1991; Shapiro, 1993; Hoffmann and Happle, 1996). We were
able to show that hair regrowth was restricted to the treated half of
the dorsal skin in nine of 12 mice. In two mice with patchy hair loss
we were not able to exclude a spontaneous remission, a well-known
problem in human patients with this form of AA (Hoffmann and
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Table III. Changes in the number of perifollicular infiltrating CD4F and CD8F cells before and after SADBE treatmenta
CD41 cells CD81 cells CD41 1 CD81 cells CD41/CD81 ratio
Before treatment 21.1 6 3.9 36.4 6 7.7 57.5 6 9.1 1:1.9 6 0.4 (1:2)
After treatment 23.2 6 4.7 24.9 6 8.5b 48.1 6 12.4 1:0.95 6 0.3 (1:1)b
aCell numbers of positive cells per hair follicle and CD41/CD81 ratio are given as the mean 6 SEM.
bpø0.05.
Happle, 1996). Because mice treated with vehicle alone did not show
any clinical signs of eczema, it could further be excluded that hair
regrowth was caused by an irritant contact dermatitis.
Similar to humans treated with the contact sensitizer SADBE
(Happle et al, 1980), mice can be sensitized with 2% SADBE, and
challenged with individually varying concentrations of the substance,
resulting in a contact dermatitis that lasts for several days. Owing to
the hair cycle-dependent pigmentation of murine skin, erythema
could not be observed in all mice whereas it is a major feature of
contact dermatitis in humans. Scaling and itching as observed 2–3 d
after treatment in humans, with a spontaneous resolution during the
following 5 d, was observed after a similar period of time in mice as
a reliable sign of successful induction of contact dermatitis. Hence,
induction and elicitation of allergic contact dermatitis after SADBE
treatment show similar dynamics in C3H/HeJ mice and humans. As
an analogy to human AA treated unilaterally with SADBE (Happle
et al, 1980), an allergic contact dermatitis was observed exclusively
on the treated side of the back in all mice.
The period of weekly elicitation of contact dermatitis necessary
to induce hair regrowth tends to be shorter in mice (4–12 wk)
than in humans (8–12 wk) (Hoffmann and Happle, 1996). This
may be explained by a shorter murine hair cycle. Darkening of the
treated skin precedes hair regrowth in all mice. Pigmentation
reflects the onset of anagen and initiation of a new hair cycle. The
association of cutaneous darkening with the onset of anagen is well
documented in mice (Chase et al, 1953; Chase, 1954; Paus et al,
1990). Although untreated AA skin and treated skin in the initial
phase of hair regrowth both contain only anagen hair follicles,
untreated AA skin showed a lighter color than treated skin. This
difference may be due to a damage of hair bulb melanocytes in
untreated AA hair follicles as it has been described in human AA
(Tobin et al, 1990, 1991) and a normalized hair bulb pigmenta-
tion in treated skin. It cannot be ruled out, however, that the
observed pigmentation is caused by postinflammatory pigmentary
incontinence that was also seen microscopically. A postinflammatory
hyperpigmentation is a rare but well-known side-effect of AA
treatment with a contact allergen in humans (Hoffmann and Happle,
1996). A severe contact dermatitis with the development of crusts,
as observed in one mouse, can be taken as another side-effect that
may occur in humans as well, especially in the beginning of
treatment (van der Steen et al, 1991; Hoffmann and Happle, 1996).
Histopathologic examination after therapy showed typical
features of contact dermatitis. The change of the inflammatory
infiltrates from around the mid and lower hair follicles to a rather
diffuse distribution throughout the interfollicular space of the
dermis and a less pronounced presence along the mid and upper parts
of the hair follicles reflects a downregulation of the perifollicular
lymphocytic infiltration after a long period of treatment with a
contact sensitizer.
The perifollicular CD41/CD81 ratio in untreated murine AA
was 1:2. This predominance of CD81 cells was previously noted
by Sundberg et al (1994) who even found a CD41/CD81 ratio
of 1:3. Moreover, we observed an affinity of CD81 cells to
the center of the infiltrate in close vicinity to the hair follicle
epithelium, whereas CD41 cells were mainly found at the
periphery of the infiltrate. Hence, a pathogenetic interaction
between CD81 T cells and the hair follicle epithelium may be
assumed, whereas the infiltration of CD41 T cells may be a
secondary phenomenon. Our results show that treatment with
a contact sensitizer modulates the composition of the perifollicular
lymphocytic infiltrate resulting in a change of the CD41/CD81
ratio from 1:2 to 1:1, due to a reduction of CD81 cells. A
modulatory effect on the composition of the perifollicular
infiltrate by treatment with a contact sensitizer has likewise been
shown in humans (Happle et al, 1986). Differences between
humans and mice arise from the fact that the perifollicular
lymphocytic infiltrate in human AA consists mainly of CD41
T cells, resulting in a CD41/CD81 ratio of 4:1 in progressive,
and 2:1 in stable untreated AA (Perret et al, 1984; Happle et al,
1986), or ranging between 5.3:1 and 1.5:1 as observed by other
groups (Peereboom-Wynia et al, 1986; Macdonald Hull et al,
1991). After treatment with the contact allergen the CD41/
CD81 ratio was decreased to 1:1 in human AA, presumably
due to an increased number of CD81 cells, whereas this ratio
increased in murine AA due to a reduction of CD81
cells. Whether this difference is meaningful concerning the
immunologic pathways of treatment with a contact allergen
remains unclear. Functional changes independent of the categoriza-
tion into CD41 and CD81 cells, such as an altered profile of
cytokine production of these cells, may be more important
(Hoffmann et al, 1994).
Our immunohistochemical studies reveal that murine hair
follicles affected by AA show a pathologic expression of MHC
class I and II and ICAM-1. The lack of MHC class I and II
expression on mid and lower hair follicle epithelium that we
have observed in normal mice is consistent with the findings of
other studies (Paus et al, 1994, 1998). Absence of ICAM-1
expression on keratinocytes in normal murine skin has also been
described by other authors (Goebeler et al, 1990). In contrast,
murine hair follicles affected by AA show aberrant expression
of MHC class I and II and ICAM-1 on almost all parts of the
follicular epithelium, and this was especially pronounced on the
ORS of the middle part of the hair follicle between the bulb
and sebaceous gland. The parts of the hair follicle that showed
abnormal expression of surface molecules were surrounded by a
lymphocytic infiltrate. Aberrant expression of HLA-ABC (MHC
class I), HLA-DR, and HLA-DQ (MHC class II), and ICAM-
1 has been described in human AA by several authors (Messenger
and Bleehen, 1985; Bro¨cker et al, 1987; Hamm et al, 1988;
Khoury et al, 1988; Gupta et al, 1990; Nickoloff and Griffiths,
1991; McDonagh et al, 1993). Differing from our observations
in murine skin, these surface molecules were predominantly
expressed on keratinocytes of the hair bulb, whereas staining of
the subinfundibular epithelium was observed less often. This
different localization of MHC class I and II and ICAM-1
expression is consistent with the differences between mice and
men regarding the localization of perifollicular lymphocytic
infiltrates. Lymphocytic infiltrates and aberrant expression of
MHC class I and II and ICAM-1 are mainly found in the
subinfundibular region of the hair follicle in mice whereas
human AA is characterized by a peribulbar lymphocytic infiltrate
and abnormal expression of surface molecules in this region.
Whether the aberrant expression of one or more of these surface
molecules is an initial event or only an epiphenomenon, as
suggested by Khoury et al (1988), remains to be elucidated. But
even if upregulation of surface molecule expression should follow
after the lymphocytic infiltration, e.g., by cytokine induction, it
might be an important pathogenetic factor in the maintenance
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of the immune reaction affecting the hair follicle in AA.
Anyhow, a close spatial correlation of aberrant surface molecule
expression and lymphocytic infiltrate could be demonstrated in
both human and mouse AA.
Our results show that after SADBE treatment there is a
conspicuous reduction of aberrant MHC class I expression on
hair follicle keratinocytes in mouse AA and a less marked but
still distinct reduction of ectopic MHC class II expression. These
findings are consistent with the down-modulation of abnormal
HLA-ABC and HLA-DR expression as observed in human AA
after treatment with the contact allergen diphenylcyclopropenone
(Bro¨cker et al, 1987). In mouse AA the pronounced down-
regulation of aberrant MHC class I expression after treatment
can be explained by a reduced number of CD81 cells as
compared with their abundance in untreated AA, especially in
the center of the inflammatory infiltrates. This may reflect a
specific interaction between CD81 T lymphocytes and MHC
class I positive hair matrix keratinocytes in the pathogenesis of
murine AA. Similar pathogenetic implications of an interaction
between cytotoxic T lymphocytes and MHC class I expression
on the hair follicle have been suggested in human AA (Bro¨cker
et al, 1987). Whether this interaction is an initial event or an
epiphenomenon is still unclear in both mouse and human AA.
The abnormal ICAM-1 expression was not downregulated by
treatment with SADBE but rather was found to be increased
on upper parts of the hair follicle. In contrast to the MHC
class molecules, ICAM-1 was not expressed on the suprasebaceous
part of the hair follicle in untreated AA, and for this reason we
regard this upregulation as an inherent feature of allergic contact
dermatitis (Goebeler et al, 1990). Because there is no further
change in ICAM-1 expression on the hair follicle, especially
not on those parts that are affected by the lymphocytic infiltrate,
ICAM-1 expression does not seem to play an important
functional part in the effect of SADBE treatment in these mice.
The part of ICAM-1 expression during treatment with a contact
sensitizer in humans is likewise poorly understood. ICAM-1 has
been described to be expressed less frequently in AA patients
who did not respond to diphenylcyclopropenone treatment, but
no statistically significant decrease of ICAM-1 expression was
observed in responders after therapy (Shapiro et al, 1993).
MHC class I and II and ICAM-1 expression on the dermal
papilla does not seem to be momentous in mouse AA because
it was likewise found in normal control mice, and because it
was reduced after therapy in only about 50% of the mice.
Moreover, the observed positive staining may simply be due to
a less effective blocking of endogenous alkaline phosphatase
activity, which is known to be very high in the dermal papilla
of murine skin (Handjiski et al, 1994). Although some authors
have described ectopic HLA-DR, HLA-DQ, and ICAM-1
expression in the dermal papilla in human AA (Messenger and
Bleehen, 1985; McDonagh et al, 1993), most investigations of
aberrant MHC class I and II and ICAM-1 expression in human
AA focused on hair follicle keratinocytes rather than on the
dermal papilla (Hamm et al, 1988; Bro¨cker et al, 1987; Khoury
et al, 1988; Gupta et al, 1990; Nickoloff and Griffiths, 1991).
In conclusion, we have shown that AA-like hair loss in C3H/
HeJ mice is characterized by aberrant surface molecule expression
similar to those observed in human AA. Analogously, this murine
disorder can be successfully treated with a contact sensitizer.
The immunohistologic changes during therapy are comparable
with those described in human AA treated with a contact
sensitizer. Whether the slight differences in the localization of
the perifollicular lymphocytic infiltrate and the reversed CD41/
CD81 ratio are meaningful, remains to be proven. Anyhow,
our study supports the concept that the hair disorder of these
mice can be taken as a model of human AA in order to
elucidate the underlying pathogenesis of the disease, to study
the mode of action of current treatment, and to develop new
therapeutic approaches.
This study was supported by a grant of the Deutsche Forschungsgemeinschaft (HO
1598/1-3) to R. Hoffmann.
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